RT Journal Article
SR Electronic
T1 Rate advancement measurement for lung cancer and pleural mesothelioma in asbestos-exposed workers
JF Thorax
JO Thorax
FD BMJ Publishing Group Ltd and British Thoracic Society
SP thoraxjnl-2021-217862
DO 10.1136/thorax-2021-217862
A1 Danila Azzolina
A1 Dario Consonni
A1 Daniela Ferrante
A1 Dario Mirabelli
A1 Stefano Silvestri
A1 Ferdinando Luberto
A1 Alessia Angelini
A1 Francesco Cuccaro
A1 Anna Maria Nannavecchia
A1 Enrico Oddone
A1 Massimo Vicentini
A1 Francesco Barone-Adesi
A1 Tiziana Cena
A1 Lucia Mangone
A1 Francesca Roncaglia
A1 Orietta Sala
A1 Simona Menegozzo
A1 Roberta Pirastu
A1 Sara Tunesi
A1 Elisabetta Chellini
A1 Lucia Miligi
A1 Patrizia Perticaroli
A1 Aldo Pettinari
A1 Vittoria Bressan
A1 Enzo Merler
A1 Paolo Girardi
A1 Lucia Bisceglia
A1 Alessandro Marinaccio
A1 Stefania Massari
A1 Corrado Magnani
A1 ,
YR 2022
UL http://thorax.bmj.com/content/early/2022/12/07/thorax-2021-217862.abstract
AB Introduction Exposure to asbestos increases the risk of lung cancer and mesothelioma. Few studies quantified the premature occurrence of these diseases in asbestos-exposed workers. Focus on premature disease onset (rate advancement or acceleration) can be useful in risk communication and for the evaluation of exposure impact. We estimated rate advancement for total mortality, lung cancer and pleural mesothelioma deaths, by classes of cumulative asbestos exposure in a pooled cohort of asbestos cement (AC) workers in Italy.Method The cohort study included 12 578 workers from 21 cohorts, with 6626 deaths in total, 858 deaths from lung cancer and 394 from pleural malignant neoplasm (MN). Rate advancement was estimated by fitting a competitive mortality Weibull model to the hazard of death over time since first exposure (TSFE).Result Acceleration time (AT) was estimated at different TSFE values. The highest level of cumulative exposure compared with the lowest, for pleural MN AT was 16.9 (95% CI 14.9 to 19.2) and 33.8 (95% CI 29.8 to 38.4) years at TSFE of 20 and 40 years, respectively. For lung cancer, it was 13.3 (95% CI 12.0 to 14.7) and 26.6 (95% CI 23.9 to 29.4) years, respectively. As for total mortality, AT was 3.35 (95% CI 2.98 to 3.71) years at 20 years TSFE, and 6.70 (95% CI 5.95 to 7.41) at 40 years TSFE.Conclusion The current study observed marked rate advancement after asbestos exposure for lung cancer and pleural mesothelioma, as well as for total mortality.Data are available on reasonable request.